HBVENTRYVISUALISED · Visualisation of the early steps of human hepatitis B virus infection: a colourful approach
6РП — Действия „Мария Кюри“
- Период
- 2004-07-01 → 2006-06-30
- Финансиране от ЕС
- 159 332 €
- Участници
- 1
- Схема
- IIF
Линиите свързват координатора с партньорите.
Накратко на български
Вирусът на хепатит B и начинът, по който той се свързва и навлиза в чернодробните клетки, се анализират чрез специални флуоресцентни багрила. Това помага да се разбере двустепенният процес на инфектиране и кои точно клетки са податливи на вируса.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Final Activity Report Summary - HBVENTRYVISUALISED (Visualisation of the early steps of human hepatitis B virus infection: a colourful approach)
Due to restrictions in cell culture systems, the study of the early infection events as well as productive infection of the hepatocyte by the hepatitis B virus (HBV) has been limited. Recent progress has been made using the HepaRG cell line (Gripon et al., PNAS, 2002). In order to study HBV binding and uptake, we utilised HepaRG cells, as well as cutting edge techniques such as incorporation of fluorescent dyes into HBV particles and quantitative, real-time PCR. We found that after four hours of incubation at 37 degrees Celsius, only around 5 % of input virus was associated with HepaRG cells, representing a maximum of 500 genome equivalents per cell. Furthermore, these genomes were distributed in specific cells, the target cells for the viruses were differentiated cells on the edge of island. In total, only 5 % of differentiated cells were positive for HBV after four hours incubation. The binding of HBV to HepaRG cells was trypsin and glycine-resistant, suggesting that binding was perhaps to a receptor of non-proteinaceous origin. However, binding could be eliminated by pre-incubation of HBV with anti-HBV antibodies, but not with an irrelevant antibody. Interestingly, pre-incubation of HepaRG cells with a highly active preS1 peptide, although totally inhibiting infection, did not inhibit binding to or uptake into differentiated cells. Furthermore, mutants that we have previously shown to be deficient in infection (Engelke et al., Hepatology, 2006) were not deficient in binding, suggesting a two-step process of HBV infection. In support of this hypothesis, HBV was found to bind to a number of cell lines, both non-human and non-liver in origin. The study of productive infection, that is infection between days 4 and 12, including the study of distribution of HBV-infected cells as well as the rate of infection and dynamics of HBV antigen expression at a cellular level requires visualisation of infected cells. We examined these aspects of HBV infection of HepaRG cells using fluorescence microscopy. We discovered that only a small percentage (10 %) of differentiated cells were infected, and displayed a striking distribution within differentiated cells. During a time course of 12 days, the number of infected cells increased only incrementally, which was the result of a highly restricted dispersion to neighbouring cells. Treatment with an inhibitory peptide post-infection indicated that this dispersion takes place to some degree via a cell-to-cell route. EGTA treatment of cells directly prior to infection leads to an increase in infection, hinting at an initial physical restriction of infection. In order to investigate whether this restriction is related to the induction of polarity during differentiation, markers for hepatocyte differentiation were studied. HepaRG cells were found to display an unusual polarisation, which was restricted to cells within a differentiated island. Such cells were resistant to infection. Taken together, these data seem to indicate an initial physical restriction of infection, followed by a biochemical restriction to unpolarised cells.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The human Hepatitis B Virus (HBV) is a major human pathogen. Despite the energetic introduction of a vaccine against HBV in the developed world, still worldwide one in twenty people is chronically infected. People living in poverty, particularly in developing countries, are particularly at risk due to lack of access to vaccines and donor organs. Carriers of the human hepatitis B virus are at high risk of developing liver cirrhosis and hepatocellular carcinoma, and worldwide more than one million people die each year of these diseases. Due to the lack of a small animal model for HBV, and the extreme difficulty until now of in vitro culture of HBV, very little is known about the early stages of HBV entry into human hepatocytes. This proposed programme aims to fill this gap in knowledge through visualisation for the first time of HBV binding and uptake. This will be achieved through the use of a newly-developed cell line, HepaRG, which is permissive to HBV infection, in combination with cutting edge cell biological techniques in the immunofluorescence and confocal microscopy fields. New approaches will include the use of coloured" viral particles - those containing EGFP or DsRed2 for the visualisation of HBV entry as well as interference assays using HBV peptides anchored in the host cell membrane. In this way, not only will valuable information on HBV entry be gained, but also an in vitro system for the analysis of agents interfering with infection will have been established."
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITAETSKLINIKUM HEIDELBERG · HEIDELBERGКоординаторГермания
Връзки
Данни: CORDIS, © Европейски съюз
